In recent years, research on the complement system has achieved significant breakthroughs, particularly concerning the central protein C1q.
Recognized as a vital initiator of the classical complement pathway, C1q also plays diverse roles in autoimmunity, inflammation, the progression of infectious diseases, and the development of therapeutic antibodies.
“C1q is more than just a complement protein—it’s a gatekeeper of immune tolerance.”— Dr. Leendert Trouw
In recent years, research on the complement system has achieved significant breakthroughs, particularly concerning the central protein C1q.
Recognized as a vital initiator of the classical complement pathway, C1q also plays diverse roles in autoimmunity, inflammation, the progression of infectious diseases, and the development of therapeutic antibodies.
“C1q is more than just a complement protein—it’s a gatekeeper of immune tolerance.”— Dr. Leendert Trouw
C1q, a key component of the complement system, is gaining attention for its pivotal role in immune regulation and its emerging potential as a therapeutic target in autoimmune diseases. At Svar Life Science, we’re exploring how this molecule could reshape the future of diagnostics and drug development.
In an exclusive interview, Dr. Leendert Trouw and Dr. Douwe Dijkstra—renowned experts in immunology—share their perspectives on:
Understanding C1q opens new doors in:
Get exclusive access to the full conversation with Dr. Trouw and Dr. Dijkstra. Learn how C1q is shaping the future of immunology and therapeutic innovation.